Health · Healthcare & Policy · 1 hr ago
Brazil bans and recalls FarmaUSA tirzepatide batch after destruction order ignored
Brazil’s health regulator banned and ordered a recall of a tirzepatide batch after the company responsible failed to destroy it as instructed.
The decision covers batch HXTZ25101, made by FarmaUSA, and was published in Brazil’s Official Gazette on Tuesday.
The regulator had earlier ordered the batch destroyed after finding problems involving its manufacture, import or storage.
The new order also bans its sale, distribution, handling and use, and requires it to be seized and collected.
Tirzepatide is used to treat type 2 diabetes and obesity, including in medicines such as Mounjaro.
It is an injectable medicine taken weekly that affects blood sugar control and appetite.
The ban aims to keep this batch out of use; the regulator’s order requires its seizure and recall.
Brazil’s health regulator banned and ordered the seizure and recall of a tirzepatide batch made by FarmaUSA after the company failed to comply with an order to destroy it.
The affected batch is HXTZ25101.
Anvisa had ordered its destruction after finding irregularities in manufacturing, importation or storage.
The new measure prohibits the product’s sale, distribution, handling and use.
Tirzepatide is used to treat type 2 diabetes and obesity or overweight with related health conditions.
- Who
- Brazil’s health regulator, Anvisa, and the company FarmaUSA.
- What
- Anvisa banned, seized and recalled FarmaUSA’s tirzepatide batch HXTZ25101 after an earlier destruction order was not followed.
- When
- The decision was published on Tuesday, October 13, 2026.
- Where
- Brazil.
- Why
- Anvisa said the company did not comply with an order to destroy the batch, which had been subject to an earlier order over irregularities in manufacturing, importation or storage.
This story does not have two clearly opposing sides.
Anvisa ordered the destruction of batch HXTZ25101 after finding irregularities in its manufacturing, importation or storage.
FarmaUSA did not comply with the destruction order.
Anvisa published a decision banning the batch and ordering its seizure and recall.
- Regulator
- Anvisa
- Company
- FarmaUSA
- Affected batch
- HXTZ25101
- Decision published
- October 13, 2026
- Product
- Tirzepatide, used to treat type 2 diabetes and obesity or overweight with related conditions
Sources
Related news
Unapproved peptide use grows as Kennedy pushes wider access
DEA proposes strict controls on concentrated kratom compounds
Kauvery Hospital launches advanced ECMO services in Chennai
FDA advisory panels often included reps tied to pharma-funded groups
Turkey plans repeat medicine pickups without new prescriptions
Karnataka refers toddler’s surgery case to medical council for inquiry
Hidden fees cost Michigan patients millions
California considers holding hospitals and insurers accountable for spending growth
Walmart to offer some diabetes drugs, inhalers and insulin at no cost in 2027
Family sues over 21-year-old woman's death after ankle fracture treatment
EU regions urge stronger local role in cardiovascular health strategy
